---
title: "Weekly Recap | Nakamoto -11.59%, most brokers rate it buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301469698.md"
description: "Nakamoto closed the week at $8.54, down 11.59% from the prior Friday’s $9.66. The S&P 500 rose 1.15% over the same stretch, leaving the stock about 12.74 percentage points behind the benchmark. It opened Monday at $9.82, touched a weekly high of $10.525, then faded through the week and closed near the low at $8.54 on Friday. The week’s range was 21.03%, with total volume of 925,847 shares, or roughly 185,169 per session."
datetime: "2026-10-10T07:14:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301469698.md)
  - [en](https://longbridge.com/en/news/301469698.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301469698.md)
generator: "portal-rs"
---

# Weekly Recap | Nakamoto -11.59%, most brokers rate it buy

## The Week

Nakamoto closed the week at $8.54, down 11.59% from the prior Friday’s $9.66. The S&P 500 rose 1.15% over the same stretch, leaving the stock about 12.74 percentage points behind the benchmark. It opened Monday at $9.82, touched a weekly high of $10.525, then faded through the week and closed near the low at $8.54 on Friday. The week’s range was 21.03%, with total volume of 925,847 shares, or roughly 185,169 per session.

## Key Events

Tuesday brought two news items framing Nakamoto as a micro-cap running parallel AI classroom and tokenised gold mine narratives — commentary rather than company-level developments. A separate TD Cowen call on Bitcoin’s path to $132,750 by 2028 circulated the same day but was not specific to the company. Thursday’s pre-market gained traction only as a volatile healthcare name during the pre-market session. On the filings front, Friday saw six amended S-1-related documents filed under the Issuer, pointing to continued revision of financing-related materials, after routine disclosures were filtered out.

## Analyst Ratings

Three brokers cover Nakamoto as at this window: two rate it buy and one overweight, with no hold, underweight or sell ratings. The consensus recommendation is strong buy, with a target of $13.33, around 56.13% above the latest price of $8.54. Target prices range from $10.00 to $17.00, indicating a wide spread of views. Within the 53-name healthcare services industry group, the stock ranks 43rd by rating.

## The Week Ahead

The coming week brings US CPI and core CPI data, with prior readings of 3.4% and 2.4% against forecasts of 3.7% and 2.5%, plus existing home sales and the NFIB small business optimism index. For a tail-end name like Nakamoto, shifts in macro rate expectations could set the broader tone for sentiment.

## In Short

The strong-buy consensus and a price target more than 50% above spot sit against the latest day’s capital flow, which shows retail and mid-size money both turning net sellers, and the stock closing near the weekly low with a price-to-book of about 0.65x. The near-term question is whether the amended filings lead into a concrete financing update, and how next week’s inflation prints shape overall risk appetite.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [NAKA.US](https://longbridge.com/en/quote/NAKA.US.md)

## Related News & Research

- [Nakamoto CEO David F. Bailey reports $25,541 common share purchase](https://longbridge.com/en/news/296539818.md)
- [Prediction: Nebius Stock Will Surge 95% in a Year, According to Wall Street. Should You Buy It Before Nov. 12?](https://longbridge.com/en/news/304627115.md)
- [Western Digital Stock Rebounds as Wall Street Bets AI Storage Demand Outlasts Election Rout](https://longbridge.com/en/news/304662557.md)
- [Microsoft is winding down Oracle deal to rent AI cloud capacity, Bloomberg News reports](https://longbridge.com/en/news/304676232.md)
- [Despite Strong Revenue Growth and a Cheap Valuation, Supermicro Stock Is Still Not a Buy](https://longbridge.com/en/news/304636271.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**